2026年1月4日，南京爱尔眼科（300015）医院屈光手术科成功完成全国首批、江苏省首例EVO+ICL(V5)晶体植入手术。此次手术由瑞士STAAR ICL国际 认证专家、南京爱尔眼科医院屈光手术科主任熊娟主刀。术中全程搭载蔡司ARTEVO800数字导航3D显微镜，实现了晶体植入过程的实时可视化与数据动 态监测，将ICL手术精准度从"术后验证"提升至"术中把关"。 3D导航显微镜下EVO+ICL(V5)晶体植入术 技术迭代：V5晶体成夜间视觉"守护者" 对于很多近视人群来说，夜晚并非宁静的时刻。夜间开车常被对向车辆的远光灯晃得眼前一片光晕，下班路上霓虹灯光散成一片星芒，甚至夜间散步也因 视物模糊而小心翼翼——这些长期困扰近视人群的"夜视力痛点"，如今有了更精准的解决方案。 "很多患者，尤其是暗瞳较大的人群，在传统屈光手术后夜间视觉质量会打折扣。"熊娟主任解释道，此次植入的EVO+ICL(V5)晶体被视为近视矫正领域 的重要升级。其核心突破在于光学区扩大至6.1mm，能够完整覆盖夜间扩张的瞳孔，有效减少眩光、光晕等视觉干扰。"V5晶体正是针对这一痛点设计， 让患者不仅在白天，在夜间也能获得清晰、舒适的视觉体验 ...

▲3D导航显微镜下EVO+ ICL (V5) 晶体植入术 术中革命：3D导航实现"手术实时透视" 传统ICL手术中，晶体的大小、拱高、位置是否合适，往往需要术后通过检查才能确认。一旦出现偏 差，患者可能面临二次调整。而此次手术中，南京爱尔眼科医院首次将3D导航系统与V5晶体植入术结 合。 2026年1月4日，南京爱尔眼科医院屈光手术科成功完成全国首批、江苏省首例EVO+ ICL (V5) 晶体植入 手术。此次手术由瑞士STAAR ICL国际认证专家、南京爱尔眼科医院屈光手术科主任熊娟主刀。术中 全程搭载蔡司ARTEVO 800数字导航3D显微镜，实现了晶体植入过程的实时可视化与数据动态监测，将 ICL手术精准度从"术后验证"提升至"术中把关"。 技术迭代：V5晶体成夜间视觉"守护者" 对于很多近视人群来说，夜晚并非宁静的时刻。夜间开车常被对向车辆的远光灯晃得眼前一片光晕，下 班路上霓虹灯光散成一片星芒，甚至夜间散步也因视物模糊而小心翼翼——这些长期困扰近视人群 的"夜视力痛点"，如今有了更精准的解决方案。 "很多患者，尤其是暗瞳较大的人群，在传统屈光手术后夜间视觉质量会打折扣。"熊娟主任解释道，此 次植入的E ...

Core Viewpoint - The government investment fund is a crucial tool for driving social capital and supporting the construction of a modern industrial system, as highlighted in the 2025 guidelines issued by the State Council [1][9]. Group 1: Government Investment Fund Role - The government investment fund serves as an important policy tool to support local industrial transformation and the development of the real economy, shifting from "large investments" to "leveraging investments" [1][10]. - The Wenzhou State-owned Financial Capital Management Company (referred to as "Guojin Company") is tasked with managing municipal government industry funds, including the key industry fund and the science and technology innovation fund, with a target scale of 30 billion yuan [1][3]. Group 2: Investment Strategies and Achievements - Guojin Company has established a multi-layered investment network focusing on local industrial transformation and ecological cultivation, with 117 projects funded by the science and technology innovation fund, amounting to 2.323 billion yuan [3][12]. - The company has successfully attracted external capital and quality projects to Wenzhou, facilitating significant investments in key sectors, such as a 10 million yuan investment in the Wenzhou Gene Drug Valley project, which subsequently attracted an additional 10 million yuan from social capital [3][12]. Group 3: Performance and Recognition - Since 2021, Guojin Company has been recognized in various industry rankings, including "Top 30 City-level Government Guidance Funds" and "Top 50 Best Government Guidance Funds," showcasing its influence and leadership in the capital market [4][13]. - The company has also facilitated the successful listing of 14 enterprises, including four local companies, contributing to the overall upgrade of related industrial chains [6][15]. Group 4: Collaborative Investment Framework - Guojin Company is building a collaborative investment framework that integrates "fiscal and financial" efforts, enhancing the system's effectiveness in supporting local industrial development through city-county collaboration and cross-regional cooperation [7][17]. - The establishment of a 3 billion yuan provincial "specialized, refined, distinctive, and innovative" mother fund has successfully attracted 2.1 billion yuan from internal and external sources, creating a new model for cross-regional fund cooperation [7][17]. Group 5: Risk Management and Operational Efficiency - To ensure the safe and efficient operation of government industry funds, Guojin Company is developing a comprehensive risk control mechanism, focusing on the selection of sub-fund management institutions and enhancing post-investment management practices [8][18]. - The company has been recognized as one of the "Top 50 Best Risk Control" entities for city and county-level government guidance funds for two consecutive years, reflecting its commitment to maintaining fund safety and operational standards [8][18].

Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][66]. Core Insights - The medical and biological sector experienced a decline of 2.06% this week, ranking 28th among 31 primary industries [1][11]. - The AI pharmaceutical company Insilico Medicine was listed on the Hong Kong Stock Exchange, raising HKD 2.277 billion, marking it as the highest fundraising biotech IPO in 2025 [4][63]. - AI technology is significantly reducing the time and costs associated with drug discovery and clinical trials, with potential savings of approximately USD 26 billion annually in compound screening and clinical trial costs [5][65]. Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.28X, with a PB (lf) of 3.17X, showing a decrease of 0.52X in PE and 0.05X in PB from the previous week [3][30]. - The medical services II sub-industry index closed at 6363.18 points, down 1.40% [22][23]. Company Performance - Top-performing companies in the medical services sector include: - Purui Eye Hospital (+5.3%) - Sanbo Brain Science (+4.7%) - Puris (+3.0%) - Tigermed (+2.9%) - Baicheng Pharmaceutical (+2.2%) - Underperforming companies include: - Bid Pharmaceutical (-6.6%) - Sunshine Nuohua (-6.1%) - Zhaoyan New Drug (-5.2%) - International Medicine (-4.0%) - Kanglong Chemical (-3.5%) [2][28]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing services, with companies like WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics being highlighted [9][66]. - It also recommends looking at third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, with companies like Aier Eye Hospital and Dean Diagnostics [9][66].

编者按 20年的模糊，10年的黑暗，医生帮她找到痛苦的根源，她通过角膜移植重新看见清晰世界；咳嗽3个 月，吃药打针始终不见好，是不是肺癌？疑惑让她沉重得喘不过气，医疗团队抽丝剥茧找出病因精准诊 疗……在生命与疾病交锋的"战场"上，每一次医患相遇，都远不止于一次问诊或治疗，更是一次深刻的 共同叙事。医生，是疗愈技术的施予者，也是患者生命故事的倾听者与协作者；患者，是疾病的亲历 者，更是借由医学重新找到秩序、尊严与希望的生命意义重建者。 即日起，长沙晚报推出年度融媒体专栏《"愈"见故事》，聚焦真实的医患共同抗击疾病的历程，融合图 文、视频等多元媒介，记录震撼人心的生命韧性，解码健康知识，诉说共情与希望——让我们"愈"见彼 此，"愈"见生命，"愈"见生活中那些微小却不可磨灭的光。 长沙晚报全媒体记者 傅容容 "10年了，我眼前的世界终于不再是一片黑暗。"近日，在长沙爱尔眼科医院，32岁的欧小茵（化名）在 医护人员的指引下，清晰辨认出视力表上"0.5"行的视标，难掩激动。 这份重见光明的喜悦，镌刻着一场跨越10年黑暗，联结医者仁心、公益力量与无私大爱的光明接力。这 场跨越20年的"寻光之旅"，藏着无数角膜盲患者的共同 ...

Group 1 - The era of extensive capital investment has ended, transitioning to a focus on "value drip irrigation" and "ecological co-construction" in the capital market, shifting from "incremental expansion" to "stock optimization" [1] - Listed companies are becoming not only platforms for the transformation of technological innovation but also leaders in hard technology investment and value co-creation [1][2] - The core of value co-creation involves three dimensions: the long-term perspective of industrial capital, the integration of capabilities from listed companies, and the shared risk through flexible capital cooperation structures [1] Group 2 - The deepening of the registration system reform and the reshaping of the valuation system in the primary and secondary markets are accelerating the trend of capital moving from virtual to real [2] - By December 31, 2025, there will be 5,470 listed companies in the domestic stock market, with a total market value exceeding 119 trillion yuan [2] - Listed companies are evolving from passive financial investors to strategic, proactive investors and collaborative partners in the innovation ecosystem [2] Group 3 - The prosperity of the innovation ecosystem requires collaboration among government, enterprises, capital, and research institutions, with listed companies playing a crucial role as resource integrators and innovation leaders [3] - The Zhangjiang Science City is building a complete innovation ecosystem that includes basic research, technology breakthroughs, commercialization of results, technology finance, and talent support [3] Group 4 - Commercial banks are transitioning from mere fund providers to comprehensive service integrators for technology finance, focusing on empowering the entire industrial chain [4] - The investment and acquisition strategies of listed companies are increasingly seen as optimal paths for quickly addressing technological shortcomings and achieving scale expansion [6] Group 5 - The investment landscape for innovative drugs is recovering, but with caution due to previous high valuations and investment cooling periods, presenting opportunities in lower-valued projects [7] - Institutional investors are encouraged to act as "strategic coaches," providing resources and market access to help innovative companies navigate challenges [7][8]

Core Insights - The era of capital-intensive growth is transitioning to a focus on value creation and ecological collaboration, emphasizing long-term investment strategies in hard technology [1][2] - Listed companies are evolving from mere capital participants to value investors and co-builders within the innovation ecosystem, driven by policy reforms and market dynamics [2][3] Group 1: Value Creation and Investment Strategies - The core of value co-creation involves three dimensions: long-term investment matching the growth cycles of hard technology, leveraging the extensive networks and insights of listed companies to support innovation, and sharing risks through flexible capital cooperation structures [1] - Listed companies are now required to adopt strategic, proactive, and collaborative investment approaches, moving away from passive financial investments to become active partners in the growth of innovative firms [2][3] Group 2: Role of Listed Companies in Innovation Ecosystem - Listed companies are recognized as key integrators of innovation resources and drivers of industrial progress, necessitating collaboration with various stakeholders including government, enterprises, and research institutions [3] - The establishment of a comprehensive innovation ecosystem is highlighted, with a focus on integrating basic research, technological breakthroughs, commercialization, and financial support [3][4] Group 3: Capital Market Dynamics - The deepening of the registration system reform and the reshaping of valuation systems in the primary and secondary markets are leading to a significant reduction in arbitrage opportunities in traditional Pre-IPO models [2] - The total number of listed companies in the domestic stock market is projected to reach 5,470 by December 31, 2025, with a total market capitalization exceeding 119 trillion yuan [2] Group 4: Empowering Innovation through Capital - Companies are increasingly using mergers and acquisitions as a strategy to quickly address technological gaps and achieve scale, with a focus on strategic alignment and technological synergy [6] - The role of institutional investors is evolving to become strategic coaches, providing not just capital but also essential resources and market access to help innovative companies navigate challenges [7][8]

Core Insights - The article emphasizes the critical role of enterprises in driving economic stability, technological innovation, industrial upgrades, and improving people's livelihoods, positioning them as the "ballast stone" of economic operation and the "main force" of technological innovation [1][2]. Group 1: NEWS Brand Sample Evaluation - The 2025 NEWS Brand Sample focuses on "new consumption, new scenarios, and new applications," assessing companies based on three key dimensions: AI+, green development, and brand social responsibility [2][3]. - The acronym "NEWS" represents four dimensions: - "N" for Innovation (New) evaluates brands on their innovation capabilities and outcomes - "E" for Energy (Energetic) assesses brands' market responsiveness and activity - "W" for Wisdom (Wise) measures strategic planning and decision-making abilities - "S" for Sustainability (Sustainable) looks at social responsibility and long-term development plans [2]. Group 2: Key Brand Highlights - The 2025 NEWS Brand Sample includes 39 companies recognized for their market leadership, innovation, sustainability, and AI+ application capabilities [6]. - Notable brands include: - China Agricultural Bank, which has significantly increased its county loan scale, surpassing 1 trillion yuan, and has seen rapid growth in various financial services [9]. - BYD Group, which achieved the production of its 15 millionth new energy vehicle and expanded its overseas sales significantly, covering over 110 countries [10]. - Tencent, which has seen international market revenue exceed 20 billion yuan and has actively engaged in social responsibility initiatives [11]. - Haidilao, which has innovated its service offerings to enhance customer experience and expand its brand portfolio [16]. - Aier Eye Hospital, which has integrated AI into its services and focused on social responsibility projects [17]. Group 3: Brand Categories - The brands are categorized into different groups based on their strengths: - 9 brands recognized for their influence include China Agricultural Bank, BYD, Tencent, and others [6]. - 9 brands noted for their responsibility include Abbott, Xifeng Wine, and others, focusing on compliance and ESG governance [19]. - 8 brands leading in innovation include Perfect China and Zebra Language, which have made significant market breakthroughs [20]. - 6 brands identified as AI+ pioneers include Xueersi and Squirrel AI, showcasing the application of AI in transforming business models [22]. - 7 brands recognized for industry breakthroughs include Nu Skin and Mousse Group, which have disrupted traditional industry paths [22].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The report highlights the development of the domestic and international gene testing industry, particularly focusing on the company GenePlus, which is a leading precision medicine company in gene testing [2][11] - The gene testing market is expected to grow significantly, with the multi-omics solution market projected to reach 123 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of 17.6% from 2024 to 2030 [22][25] - GenePlus has established a comprehensive capability from biomarker discovery to commercialization, leveraging its proprietary multi-omics platform and AI technology [2][11] Summary by Sections Market Performance - The overall pharmaceutical sector underperformed the market, with a 0.18% decline in the biopharmaceutical sector, while the A-share market rose by 2.17% [1] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 36.95x, which is at the 78.96th percentile of its historical valuation over the past five years [1] Company Overview - GenePlus was founded in 2015 and has raised approximately 1.25 billion yuan through multiple financing rounds, with a post-financing valuation of 4.3 billion yuan as of November 2025 [2][16] - The company has developed several products, including a gene mutation detection kit for lung cancer, which received regulatory approval in 2019 [28] Financial Performance - In the first half of 2025, GenePlus reported revenues of 285 million yuan, a year-on-year increase of 12.7%, but incurred a net loss of 414 million yuan [36] - The company's gross margin improved from 42% to 68.5% due to economies of scale in clinical laboratory services [37] Product Pipeline - GenePlus offers three main solutions: precision diagnosis, drug development empowerment, and clinical research and transformation, covering various applications including tumor detection and organ transplant monitoring [18][20] - The company is developing a non-invasive monitoring product for kidney transplant damage, expected to launch in 2025, which shows high sensitivity and specificity [30] Market Trends - The report notes significant international activity in the gene testing market, with major acquisitions and partnerships indicating a growing interest in cancer diagnostics [42] - Regulatory advancements in China for tumor gene testing are anticipated to align with international standards, potentially accelerating product development and approval processes [41]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The report highlights the development of the domestic and international gene testing industry, particularly focusing on the company GenePlus, which is a leading precision medicine company in gene testing [2][11] - The gene testing market is expected to grow significantly, with a compound annual growth rate (CAGR) of 14.8% from 2019 to 2024, reaching a market size of approximately 464 billion yuan by 2024 [22] - GenePlus has established a comprehensive capability from biomarker discovery to commercialization, leveraging its proprietary multi-omics platform and AI technology [2][11] Summary by Sections Market Performance - The pharmaceutical sector underperformed the overall market, with a slight decline of 0.18% in the biopharmaceutical sector, while the A-share market rose by 2.17% [1] Company Overview - GenePlus was founded in 2015 and has raised approximately 1.25 billion yuan through multiple financing rounds, with a post-investment valuation of 4.3 billion yuan after the latest round in November 2025 [2][16] - The company has developed several products, including a gene mutation detection kit for lung cancer, which received regulatory approval in 2019 [28] Financial Performance - In the first half of 2025, GenePlus achieved a revenue of 285 million yuan, representing a year-on-year growth of 12.7%, although it reported a net loss of 414 million yuan [36] - The company's gross margin improved from 42% to 68.5% due to economies of scale in clinical laboratory services [37] Product Pipeline - GenePlus offers three main solutions: precision diagnosis, drug development empowerment, and clinical research and transformation, covering various applications including tumor detection and organ transplant monitoring [18][20] - The company is developing a non-invasive monitoring product for kidney transplant damage, expected to launch in 2025, which shows high sensitivity and specificity [30] Market Trends - The report notes significant international activity in the cancer diagnostics market, with major acquisitions and partnerships indicating a growing interest in gene testing technologies [42] - Regulatory advancements in China for tumor gene testing are anticipated to align more closely with international standards, potentially accelerating product development and approval processes [41]